Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 253,730 | 84,518 | 118,764 | 88,205 | 64,333 |
| Marketable Securities | 751,027 | 485,374 | 479,227 | 688,723 | 583,155 |
| Receivables | 3,118 | 3,762 | 3,453 | 2,810 | 1,176 |
| Inventories | 26,429 | 23,937 | 23,070 | 19,076 | 17,274 |
| TOTAL | $1,074,189 | $632,127 | $663,627 | $833,835 | $704,352 |
| Non-Current Assets | |||||
| PPE Net | 11,819 | 12,726 | 14,119 | 15,382 | 16,785 |
| Investments And Advances | 655,889 | 75,404 | 116,301 | 29,435 | 224,902 |
| Other Non-Current Assets | 49,897 | 52,806 | 55,662 | 58,466 | 61,219 |
| TOTAL | $717,605 | $140,936 | $186,082 | $103,283 | $302,906 |
| Total Assets | $1,791,794 | $773,063 | $849,709 | $937,118 | $1,007,258 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 17,143 | 10,035 | 11,155 | 9,780 | 13,271 |
| Accrued Expenses | 33,307 | 36,742 | 25,129 | 43,167 | 30,490 |
| TOTAL | $119,451 | $62,637 | $51,691 | $67,955 | $58,425 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 45,671 | 49,916 | 54,096 | 58,144 | 61,990 |
| TOTAL | $45,671 | $49,916 | $54,096 | $58,144 | $61,990 |
| Total Liabilities | $165,122 | $112,553 | $105,787 | $126,099 | $120,415 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 57,030 | 56,893 | 56,773 | 56,195 | 55,891 |
| Common Shares | 73 | 73 | 73 | 72 | 72 |
| Retained earnings | -52,401 | -1,000,316 | -904,198 | -822,649 | -726,709 |
| Other shareholders' equity | 2,934 | -1,531 | -1,573 | -927 | -6,382 |
| TOTAL | $1,626,672 | $660,510 | $743,922 | $811,019 | $886,843 |
| Total Liabilities And Equity | $1,791,794 | $773,063 | $849,709 | $937,118 | $1,007,258 |